C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 60 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Pipeline Review, H1 2016', provides in depth analysis on C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) targeted pipeline therapeutics. 

The report provides comprehensive information on the C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1)
- The report reviews C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) Overview 7
Therapeutics Development 8
C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Products under Development by Stage of Development 8
C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Products under Development by Therapy Area 9
C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Products under Development by Indication 10
C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Products under Development by Companies 13
C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Products under Development by Universities/Institutes 15
C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 21
C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Companies Involved in Therapeutics Development 23
AFFiRiS AG 23
ChemoCentryx, Inc. 24
Dompe Farmaceutici S.p.A. 25
Noxxon Pharma AG 26
C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Drug Profiles 27
CCX-168 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
DF-2593A - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Drug to Antagonize C5aR for Periodontitis - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
EP-67 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
NOXD-19 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
NOXD-20 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Small Molecule to Target C5aR for Undisclosed Indication - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Synthetic Peptide to Antagonize C5aR for Amyotrophic Lateral Sclerosis - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Vaccine to Target C5a for Alzheimer's Disease - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Dormant Projects 40
C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Discontinued Products 42
C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Featured News & Press Releases 43
Jun 01, 2016: ChemoCentryx Receives European Medicines Agency PRIority MEdicines (PRIME) Designation for Accelerated Assessment of Complement 5a Receptor Inhibitor CCX168 for Treatment of Patients with ANCA-Associated Vasculitis 43
May 23, 2016: ChemoCentryx Announces Presentation of Positive Results from Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 at the 53rd ERA-EDTA Congress 44
Apr 28, 2016: ChemoCentryx Receives FDA Orphan Products Development Grant for Orally Administered Complement 5a Receptor Inhibitor CCX168 for Treatment of ANCA-Associated Vasculitis 46
Jan 06, 2016: ChemoCentryx Announces Positive Results in Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 46
Aug 19, 2015: UNMC spinoff company to test H1N1 vaccine in animal trial 48
Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis 49
Nov 20, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in Atypical Hemolytic Uremic Syndrome Treatment by the FDA 49
Nov 17, 2014: ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit In Non-Renal ANCA Vasculitis Disease Activity, In Addition To Previously Shown Kidney Disease Improvements 50
Sep 04, 2014: Two Presentations at International Conferences of Preclinical Data on NOXXON 's anti - C5a Spiegelmer, a Potential Drug in Pneumococcal Pneumonia - Induced S epsis 51
Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA 52
Jun 02, 2014: ChemoCentryx's Orally-Administered Complement 5a Receptor Inhibitor, CCX168, Shows Benefit in ANCA-Associated Vasculitis Based on Birmingham Vasculitis Activity Score and Renal Disease Measurements 52
Dec 03, 2013: ChemoCentryx Announces Positive Top-Line CCX168 Phase II Data in ANCA-Associated Renal Vasculitis 53
Dec 07, 2012: Penn-Led Research Suggests A New Strategy To Prevent Or Halt Periodontal Disease 55
May 26, 2012: ChemoCentryx Presents Data on CCX168 At 49th European Renal Association-European Dialysis And Transplant Association Congress 56
Oct 17, 2011: ChemoCentryx Initiates Phase II Clinical Trial For CCX168 In Vasculitis 57
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 59
Disclaimer 60

List of Tables

Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Indication, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Assessment by Monotherapy/Combination Products, H1 2016 17
Number of Products by Stage and Mechanism of Action, H1 2016 19
Number of Products by Stage and Route of Administration, H1 2016 20
Number of Products by Stage and Molecule Type, H1 2016 22
Pipeline by AFFiRiS AG, H1 2016 23
Pipeline by ChemoCentryx, Inc., H1 2016 24
Pipeline by Dompe Farmaceutici S.p.A., H1 2016 25
Pipeline by Noxxon Pharma AG, H1 2016 26
Dormant Projects, H1 2016 40
Dormant Projects (Contd..1), H1 2016 41
Discontinued Products, H1 2016 42